Collagenase Enzyme Injection for Bladder Dysfunction Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for tracheal and subglottic stenosis, as well as benign prostatic hyperplasia, are often invasive and ineffective, particularly in advanced cases, as they fail to adequately target and dissolve collagen-based scar tissue, leading to complications such as urinary retention and obstructive symptoms.
Innovation Solution
The use of Collagenase Clostridium histolyticum (CCH), a combination of Clostridial class I and II collagenases, is injected locally at the affected sites to break down collagen, reducing scar tissue and alleviating symptoms through targeted proteolytic activity without systemic exposure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional surgical treatments (tracheal resection, balloon dilation, laser removal) are used to treat tracheal and subglottic stenosis, then the stenotic area can be reduced, but the treatment becomes invasive with significant scarring and complications
Solution Approach 1:
The patent replaces mechanical surgical interventions (balloon dilation, laser removal, resection) with a biochemical system using collagenase enzymes to dissolve scar tissue. This substitution eliminates the need for invasive mechanical procedures while maintaining treatment effectiveness for reducing stenotic areas.
Solution Approach 2:
The patent introduces collagenase enzyme as an intermediary substance that mediates the breakdown of collagen-based scar tissue. This intermediary enables the dissolution of stenotic tissue without direct mechanical intervention, reducing invasiveness and associated complications.
2Reliability
If invasive surgical procedures are performed to treat benign prostatic hyperplasia, then prostate tissue can be removed, but the risk of impotence, incontinence and re-treatment increases
Solution Approach 1:
The patent replaces mechanical surgical removal of prostate tissue with a biochemical dissolution process using collagenase. This substitution targets the collagen network specifically, allowing tissue breakdown without the trauma of surgical cutting, thereby reducing risks of impotence and incontinence.
Solution Approach 2:
The patent applies collagenase locally to the prostate tissue, targeting specifically the collagen network within the enlarged prostate. This localized biochemical action spares surrounding structures and functional tissues, minimizing adverse consequences such as incontinence and impotence.
3Reliability
If repeated invasive procedures are performed to treat advanced stenosis, then the stenotic area can be reduced, but the treatment complexity and patient burden increases
Solution Approach 1:
The patent replaces multiple invasive mechanical procedures with a single biochemical treatment approach. The collagenase enzyme can be administered in a non-invasive or minimally invasive manner, eliminating the need for repeated surgical interventions and reducing overall treatment complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
CCH effectively reduces the size of stenotic areas and improves bladder and prostate function by dissolving excess collagen, offering a minimally invasive and safer alternative to conventional treatments with minimal side effects.
Implementation Method 1
Collagenase Clostridium histolyticum (CCH), a combination of Clostridial class I and II collagenases, is injected locally at the affected sites to break down collagen
Data Source
AI summary
Collagenase Clostridium histolyticum (EN3835) is a proteinase that can hydrolyze the triple-helical region of collagen under physiological conditions. EN3835 targets the collagenase structural matrix at the site of injection and does not require systemic exposure. Embodiments include methods of lysing subdermal and submucosal collagen to treat various conditions such as bladder dysfunction, esophageal stenosis, benign prostatic hyperplasia, tracheal stenosis, subglottic stenosis and scleroderma.